2023 FDA approvals: unprecedented volume at moderate value

Mathias Baedeker,Michael S. Ringel,Clemens C. Möller

DOI: https://doi.org/10.1038/d41573-024-00011-9

IF: 112.288

2024-01-17

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 17 January 2024; doi:10.1038/d41573-024-00011-9 2023 FDA approvals: unprecedented volume at moderate value

pharmacology & pharmacy,biotechnology & applied microbiology

What problem does this paper attempt to address?

Current Regulatory Status in China of Drugs Withdrawn from the US FDA Accelerated Pathway: Implications for Regulation Globally

Xingxian Luo,Lin Huang,Xin Du,Yue Yang,Xufeng Lv,Xiaohong Zhang

DOI: https://doi.org/10.1016/s1470-2045(24)00025-1

2024-01-01

Abstract:In 1992, in an effort to bring novel drugs to market more quickly and meet patient needs in a timely manner, the US Food and Drug Administration (FDA) pioneered an accelerated approval initiative on the basis of surrogate endpoints that are reasonably predictive of clinical benefit for the treatment of serious or life-threatening diseases. 1 US Food and Drug AdministrationAccelerated approval program. https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-programDate accessed: October 24, 2023 Google Scholar By contrast to regular approval, accelerated approval requires post-market confirmatory clinical trials to establish the clinical benefit of the drug, then a decision is made as to whether the approval should be converted to a traditional approval or whether the drug should be withdrawn from the market. 2 US Food and Drug AdministrationExpedited programs for serious conditions––drugs and biologics. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologicsDate accessed: October 24, 2023 Google Scholar In the past 3 years, this expedited pathway has attracted extensive criticism, including failure to complete confirmatory clinical trials in a timely manner, 3 Fashoyin-Aje LA Mehta GU Beaver JA Pazdur R The on- and off-ramps of oncology accelerated approval. N Engl J Med. 2022; 387: 1439-1442 Crossref PubMed Scopus (33) Google Scholar , 4 Gyawali B Kesselheim AS Ross JS The accelerated approval program for cancer drugs—finding the right balance. N Engl J Med. 2023; 389: 968-971 Crossref PubMed Scopus (9) Google Scholar use of surrogate endpoints (eg, progression-free survival) in confirmatory clinical trials, 5 Parikh RB Hubbard RA Wang E et al. Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration accelerated approval. JAMA Oncol. 2023; 9: 567-569 Crossref PubMed Scopus (6) Google Scholar and failure to withdraw drugs quickly from the markets when they have been shown to not have clinical benefit. 6 Akhade A Sirohi B Gyawali B Global consequences of the US FDA's accelerated approval of cancer drugs. Lancet Oncol. 2022; 23: 201-203 Summary Full Text Full Text PDF PubMed Scopus (10) Google Scholar Concerns have also been raised that cancer drugs given accelerated approval by the FDA could lead to difficult decisions in other countries, especially in some low-income and middle-income countries that do not have their own regulatory agencies or that have weak regulatory capacity. 6 Akhade A Sirohi B Gyawali B Global consequences of the US FDA's accelerated approval of cancer drugs. Lancet Oncol. 2022; 23: 201-203 Summary Full Text Full Text PDF PubMed Scopus (10) Google Scholar , 7 Cramer A Sørup FKH Christensen HR Petersen TS Karstoft K Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?. Lancet Oncol. 2023; 24: e385-e394 Summary Full Text Full Text PDF PubMed Scopus (3) Google Scholar
Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)

Matthew H Rim,Collin Dean,Enela Aliaj,Brittany L Karas,Farah Barada,Andrew M Levitsky

DOI: https://doi.org/10.1093/ajhp/zxae242

2024-11-07

Abstract:Purpose: Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by sharing new and anticipated novel drug approvals. Summary: Selected drug approvals anticipated in the 12-month period covering the third quarter of 2024 through the second quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics selected from 54 novel drugs awaiting US Food and Drug Administration approval. New cell therapies for treating cancers continue to enter the drug pipeline, while novel targeted therapies for biliary tract, gastric, pancreatic, and breast cancers, as well as 3 subcutaneous versions of already approved drugs given intravenously, are awaiting approval. Additionally, many novel drugs are being developed for treatment of rare and ultra-rare diseases such as hereditary angioedema, macular telangiectasia, congenital adrenal hyperplasia, and Barth syndrome. Two new subcutaneous drugs for hemophilia, a new oral medication for hereditary angioedema, a novel monoclonal antibody for atopic dermatitis, and the first oral penem antibiotic are also in the pipeline. Conclusion: New drugs with various indications for cancers and rare diseases continue to strengthen the drug pipeline.
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023

Gizem Kayki-Mutlu,Zinnet Sevval Aksoyalp,Leszek Wojnowski,Martin C. Michel

DOI: https://doi.org/10.1007/s00210-024-03063-1

2024-03-26

Abstract:Abstract With 54 new drugs and seven cellular and gene therapy products, the approvals by the US Food and Drug Administration (FDA) recovered 2023 from the 2022 dent back to the levels of 2020–2021. As in previous years of this annual review, we assign these new drugs to one of three levels of innovation: first drug against a condition (“first-in-indication”), first drug using a novel molecular mechanism (“first-in-class”), and “next-in-class,” i.e., a drug using an already exploited molecular mechanism. We identify four (7%) “first-in-indication,” 22 (36%) “first-in-class,” and 35 (57%) “next-in-class” drugs. By treatment area, rare diseases (54%) and cancer drugs (23%) were once again the most prevalent (and partly overlapping) therapeutic areas. Other continuing trends were the use of accelerated regulatory approval pathways and the reliance on biopharmaceuticals (biologics). 2023 marks the approval of a first therapy based on CRISPR/Cas9 gene editing.

pharmacology & pharmacy
Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

Andreas Papapetropoulos,Stavros Topouzis,Steve P. H. Alexander,Miriam Cortese‐Krott,Dave A. Kendall,Kirill A. Martemyanov,Claudio Mauro,Nithyanandan Nagercoil,Reynold A. Panettieri Jr,Hemal H. Patel,Rainer Schulz,Barbara Stefanska,Gary J. Stephens,Mauro M. Teixeira,Nathalie Vergnolle,Xin Wang,Péter Ferdinandy

DOI: https://doi.org/10.1111/bph.16337

IF: 7.3

2024-03-23

British Journal of Pharmacology

Abstract:In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer. Thirty drugs are categorized as "first‐in‐class" (FIC), illustrating the quality of research and innovation that drives new chemical entity discovery and development. We succinctly describe the mechanism of action of most of these FIC drugs and discuss the therapeutic areas covered, as well as the chemical category to which these drugs belong. The 2023 novel drug list also demonstrates an unabated emphasis on polypeptides (recombinant proteins and antibodies), Advanced Therapy Medicinal Products (gene and cell therapies) and RNA therapeutics, including the first‐ever approval of a CRISPR‐Cas9‐based gene‐editing cell therapy.

pharmacology & pharmacy
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects

Yi-Ru Bai,Dong-Jie Seng,Ying Xu,Yao-Dong Zhang,Wen-Juan Zhou,Yang-Yang Jia,Jian Song,Zhang-Xu He,Hong-Min Liu,Shuo Yuan

DOI: https://doi.org/10.1016/j.ejmech.2024.116706

2024-10-05

Abstract:In 2023, the U.S. Food and Drug Administration has approved 55 novel medications, consisting of 17 biologics license applications and 38 new molecular entities. Although the biologics license applications including antibody and enzyme replacement therapy set a historical record, the new molecular entities comprising small molecule drugs, diagnostic agent, RNA interference therapy and biomacromolecular peptide still account for over 50 % of the newly approved medications. The novel and privileged scaffolds derived from drugs, active molecules and natural products are consistently associated with the discovery of new mechanisms, the expansion of clinical indications and the reduction of side effects. Moreover, the structural modifications based on the promising scaffolds can provide the clinical candidates with the improved biological activities, bypass the patent protection and greatly shorten the period of new drug discovery. Therefore, conducting an appraisal of drug approval experience and related information will expedite the identification of more potent drug molecules. In this review, we comprehensively summarized the pertinent information encompassing the clinical application, mechanism, elegant design and development processes of 28 small molecule drugs, and expected to provide the promising structural basis and design inspiration for pharmaceutical chemists.
2023 in review: FDA approvals of new medicines

Michael S Kinch,Zachary Kraft,Tyler Schwartz

DOI: https://doi.org/10.1016/j.drudis.2024.103966

IF: 8.369

2024-03-31

Drug Discovery Today

Abstract:An analysis of all new entities approved by both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) identified the approval of 68 {AuQ: Should this be 69 as shown in Figure 1A&B?} new entities in the year 2023, 50 % more than in the previous year. Oncology drugs tied with congenital and infectious diseases drugs for the most approvals. Although orphan and priority approvals continued at a high pace, the rate of fast-track approvals...

pharmacology & pharmacy
2020 FDA drug approvals

Asher Mullard

DOI: https://doi.org/10.1038/d41573-021-00002-0

IF: 112.288

2021-01-05

Nature Reviews Drug Discovery

Abstract:The FDA approved 53 novel drugs in 2020, the second highest count in over 20 years. The FDA approved 53 novel drugs in 2020, the second highest count in over 20 years.

pharmacology & pharmacy,biotechnology & applied microbiology
Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023

Alexander C Martins,Mariana Y Oshiro,Fernando Albericio,Beatriz G de la Torre

DOI: https://doi.org/10.3390/biomedicines12091992

IF: 4.757

2024-09-02

Biomedicines

Abstract:An increase in total drug (small molecules and biologics) approvals by the Food and Drug Administration (FDA) was seen in 2023 compared with the previous year. Cancer remained the disease most targeted by monoclonal antibodies (mAbs), followed by autoimmune conditions. Our data reveal the prevalence of approvals for biologics even during years when the total number of authorizations was low, such as in 2022. Over half the drugs that received the green light in 2023 benefited from expedited programs, as the incidence of many diseases increased. In addition, over half of the biologics approved received Orphan Drug Designation from the FDA. This narrative review delves into details of the most significant approvals in 2023, including mAbs, enzymes, and proteins, explaining their mechanisms of action, differences from previous drugs, placebo, and standards of care, and outcomes in clinical trials. Given the varying number of drugs authorized annually by the U.S. health authority, this review also examines the limits of external influences over the FDA's decisions and independence regarding drug approvals and withdrawals.
Synthesis and clinical application of new drugs approved by FDA in 2023

Ya-Tao Wang,Peng-Cheng Yang,Yan-Feng Zhang,Jin-Feng Sun

DOI: https://doi.org/10.1016/j.ejmech.2024.116124

IF: 7.088

2024-01-07

European Journal of Medicinal Chemistry

Abstract:In 2023, the U.S. Food and Drug Administration (FDA) granted approval to a total of 55 new drugs, comprising 29 new chemical entities (NCEs) and 25 new biological entities (NBEs). These drugs primarily focus on oncology, the central nervous system, anti-infection, hematology, cardiovascular, ophthalmology, immunomodulatory and other therapeutic areas. Out of the 55 drugs, 33 (60 %) underwent an accelerated review process and received approval, while 25 (45 %) were specifically approved for the treatment of rare diseases. The purpose of this review is to provide an overview of the clinical uses and production techniques of 29 newly FDA-approved NCEs in 2023. Our intention is to offer a comprehensive understanding of the synthetic approaches employed in the creation of these drug molecules, with the aim of inspiring the development of novel, efficient, and applicable synthetic methodologies.

chemistry, medicinal
Fresh from the biotech pipeline: record-breaking FDA approvals

Melanie Senior

DOI: https://doi.org/10.1038/s41587-024-02166-7

IF: 46.9

2024-02-27

Nature Biotechnology

Abstract:New drug approvals reached an all-time high in 2023, with five gene therapies, the first CRISPR–Cas9-edited therapy and a disease-modifying Alzheimer's drug.

biotechnology & applied microbiology
The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules

Beatriz G. de la Torre,Fernando Albericio

DOI: https://doi.org/10.3390/molecules29030585

IF: 4.6

2024-01-26

Molecules

Abstract:With the COVID-19 pandemic behind us, the U.S. Food and Drug Administration (FDA) has approved 55 new drugs in 2023, a figure consistent with the number authorized in the last five years (53 per year on average). Thus, 2023 marks the second-best yearly FDA harvest after 2018 (59 approvals) in all the series. Monoclonal antibodies (mAbs) continue to be the class of drugs with the most approvals, with an exceptional 12, a number that makes it the most outstanding year for this class. As in 2022, five proteins/enzymes have been approved in 2023. However, no antibody–drug conjugates (ADCs) have been released onto the market. With respect to TIDES (peptides and oligonucleotides), 2023 has proved a spectacular year, with a total of nine approvals, corresponding to five peptides and four oligonucleotides. Natural products continue to be the best source of inspiration for drug development, with 10 new products on the market. Three drugs in this year's harvest are pegylated, which may indicate the return of pegylation as a method to increase the half-lives of drugs after the withdrawal of peginesatide from the market in 2013. Following the trends in recent years, two bispecific drugs have been authorized in 2023. As in the preceding years, fluorine and/or N-aromatic heterocycles are present in most of the drugs. Herein, the 55 new drugs approved by the FDA in 2023 are analyzed exclusively on the basis of their chemical structure. They are classified as the following: biologics (antibodies, proteins/enzymes); TIDES (peptide and oligonucleotides); combined drugs; pegylated drugs; natural products; nitrogen aromatic heterocycles; fluorine-containing molecules; and other small molecules.

chemistry, multidisciplinary,biochemistry & molecular biology
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions

Dean G. Brown,Heike J. Wobst

DOI: https://doi.org/10.1021/acs.jmedchem.0c01516

IF: 8.039

2021-02-22

Journal of Medicinal Chemistry

Abstract:A total of 378 novel drugs and 27 biosimilars approved by the U.S. Food and Drug Administration (FDA) between 2010 and 2019 were evaluated according to approval numbers by year, therapeutic areas, modalities, route of administration, first-in-class designation, approval times, and expedited review categories. From this review, oncology remains the top therapy area (25%), followed by infection (15%) and central nervous system disorders (11%). Regulatory incentives have been effective as evidenced by an increase in orphan drugs as well as antibacterial drugs approved under the GAIN act. Clinical development times may be increasing, perhaps as a result of the increase in orphan drug indications. Small molecules continue to mostly adhere to "Rule of 5" (Ro5) parameters, but innovation in new modalities is rapidly progressing with approvals for antisense oligonucleotides (ASO), small-interfering RNA (siRNAs), and antibody-directed conjugates (ADCs). Finally, novel targets and scientific breakthroughs that address areas of unmet clinical need are discussed in detail.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01516?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01516</a>.Complete list of 2010–2019 FDA Approved NME, BLA and biosimilars categorized by year, class, FIC, target, indication, orphan designation, and route of administration (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01516/suppl_file/jm0c01516_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

chemistry, medicinal
FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit

Kelly J. Norsworthy,Rosa J. Lee-Alonzo,Richard Pazdur

DOI: https://doi.org/10.1038/s41571-024-00871-5

IF: 78.8

2024-02-23

Nature Reviews Clinical Oncology

Abstract:In 2023, the US FDA approved several new cancer drugs and biologic agents, including seven small-molecule inhibitors, four bispecific T cell engagers, two anti-PD-1 antibodies and one cell therapy product. Regulatory focus areas included analyses of biomarker-positive subgroups that drive efficacy, equipoise in randomized controlled trials and a new authority to require confirmatory trials be underway before accelerated approval.

oncology
Approvals by the China NMPA in 2023

Xiecheng Zhi,Qiu Li,Liming Shao

DOI: https://doi.org/10.1038/d41573-024-00034-2

IF: 112.288

2024-02-21

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 19 February 2024; doi:10.1038/d41573-024-00034-2 Approvals by the China NMPA in 2023

pharmacology & pharmacy,biotechnology & applied microbiology
The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Beatriz G de la Torre,Fernando Albericio,Beatriz G. de la Torre

DOI: https://doi.org/10.3390/molecules26030627

IF: 4.6

2021-01-25

Molecules

Abstract:Although the pharmaceutical industry will remember 2020 as the year of COVID-19, it is important to highlight that this year has been the second-best—together with 1996—in terms of the number of drugs accepted by the US Food and Drug Administration (FDA). Each of these two years witnessed the authorization of 53 drugs—a number surpassed only in 2018 with 59 pharmaceutical agents. The 53 approvals in 2020 are divided between 40 new chemical entities and 13 biologic drugs (biologics). Of note, ten monoclonal antibodies, two antibody–drug conjugates, three peptides, and two oligonucleotides have been approved in 2020. Close inspection of the so-called small molecules reveals the significant presence of fluorine atoms and/or nitrogen aromatic heterocycles. This report analyzes the 53 new drugs of the 2020 harvest from a strictly chemical perspective, as it did for those authorized in the previous four years. On the basis of chemical structure alone, the drugs that received approval in 2020 are classified as the following: biologics (antibodies, antibody-drug conjugates, and proteins); TIDES (peptide and oligonucleotides); natural products; fluorine-containing molecules; nitrogen aromatic heterocycles; and other small molecules.

chemistry, multidisciplinary,biochemistry & molecular biology
Recent and anticipated novel drug approvals for 2024

Matthew H Rim,Brittany L Karas,Farah Barada,Andrew M Levitsky

DOI: https://doi.org/10.1093/ajhp/zxae046

2024-02-19

American Journal of Health-System Pharmacy

Abstract:Abstract Disclaimer In an effort to expedite the publication of articles pandemic, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing periodic updates on new and anticipated novel drug approvals. Summary Selected drug approvals anticipated in the 12-month period covering the first quarter of 2024 through the fourth quarter of 2024 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 59 novel drugs awaiting US Food and Drug Administration approval. This year’s pipeline includes recently added drugs with various indications including oncology, infectious diseases, genetic disorders, and rare diseases. New cellular and gene therapies are rapidly evolving and being studied for several rare diseases and cancers. Conclusion More oncology agents, including gene therapies, oral agents, and monoclonal antibodies, are in the pipeline this year. Additional diseases targeted by new novel drugs, including cellular and gene therapies, are hemophilia, nonalcoholic steatohepatitis, Alzheimer’s disease, and rare diseases such as galactosemia and epidermolysis bullosa.

pharmacology & pharmacy
A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect

Yi-Ru Bai,Xin Yang,Ke-Tong Chen,Xiao-Dan Cuan,Yao-Dong Zhang,Li Zhou,Li Yang,Hong-Min Liu,Shuo Yuan

DOI: https://doi.org/10.1016/j.ejmech.2024.116759

2024-08-10

Abstract:In 2022, the U.S. Food and Drug Administration approved a total of 16 marketing applications for small molecule drugs, which not only provided dominant scaffolds but also introduced novel mechanisms of action and clinical indications. The successful cases provide valuable information for optimizing efficacy and enhancing pharmacokinetic properties through strategies like macrocyclization, bioequivalent group utilization, prodrug synthesis, and conformation restriction. Therefore, gaining an in-depth understanding of the design principles and strategies underlying these drugs will greatly facilitate the development of new therapeutic agents. This review focuses on the research and development process of these newly approved small molecule drugs including drug design, structural modification, and improvement of pharmacokinetic properties to inspire future research in this field.
New drug approvals for 2021: Synthesis and clinical applications

Shuo Yuan,Dan-Shu Wang,Hui Liu,Sheng-Nan Zhang,Wei-Guang Yang,Meng Lv,Yu-Xue Zhou,Sai-Yang Zhang,Jian Song,Hong-Min Liu

DOI: https://doi.org/10.1016/j.ejmech.2022.114898

IF: 7.088

2022-11-06

European Journal of Medicinal Chemistry

Abstract:50 New drugs including 36 chemical entities and 14 biologics were approved by the U.S. Food and Drug Administration during 2021. Among the marketed drugs, 31 new small molecule agents (29 small molecule drugs and 2 diagnostic agents) with privileged structures and novel clinical applications represent as promising leads for the development of new drugs with the similar indications and improved therapeutic efficacy. This review is mainly focused on the clinical applications and synthetic methods of 29 small molecule drugs newly approved by the FDA in 2021. We believed that insight into the synthetic approaches of drug molecules would provide creative and practical inspirations for the development of more efficient and practical synthetic technologies to meet with new drug discovery.

chemistry, medicinal
Top companies and drugs by sales in 2023

Paul Verdin

DOI: https://doi.org/10.1038/d41573-024-00041-3

IF: 112.288

2024-03-09

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 08 March 2024; doi:10.1038/d41573-024-00041-3 Top companies and drugs by sales in 2023

pharmacology & pharmacy,biotechnology & applied microbiology
DrugCentral 2023 extends human clinical data and integrates veterinary drugs

Sorin Avram,Thomas B Wilson,Ramona Curpan,Liliana Halip,Ana Borota,Alina Bora,Jayme Holmes,Jeffrey Knockel,Cristian G Bologa,Jeremy J Yang,Tudor I Oprea

DOI: https://doi.org/10.1093/nar/gkac1085

IF: 14.9

2022-12-10

Nucleic Acids Research

Abstract:DrugCentral monitors new drug approvals and standardizes drug information. The current update contains 285 drugs (131 for human use). New additions include: (i) the integration of veterinary drugs (154 for animal use only), (ii) the addition of 66 documented off-label uses and iii) the identification of adverse drug events from pharmacovigilance data for pediatric and geriatric patients. Additional enhancements include chemical substructure searching using SMILES and 'Target Cards' based on UniProt accession codes. Statistics of interests include the following: (i) 60% of the covered drugs are on-market drugs with expired patent and exclusivity coverage, 17% are off-market, and 23% are on-market drugs with active patents and exclusivity coverage; (ii) 59% of the drugs are oral, 33% are parenteral and 18% topical, at the level of the active ingredients; (iii) only 3% of all drugs are for animal use only; however, 61% of the veterinary drugs are also approved for human use; (iv) dogs, cats and horses are by far the most represented target species for veterinary drugs; (v) the physicochemical property profile of animal drugs is very similar to that of human drugs. Use cases include azaperone, the only sedative approved for swine, and ruxolitinib, a Janus kinase inhibitor.

biochemistry & molecular biology

2023 FDA approvals: unprecedented volume at moderate value

Current Regulatory Status in China of Drugs Withdrawn from the US FDA Accelerated Pathway: Implications for Regulation Globally

Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects

2023 in review: FDA approvals of new medicines

2020 FDA drug approvals

Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023

Synthesis and clinical application of new drugs approved by FDA in 2023

Fresh from the biotech pipeline: record-breaking FDA approvals

The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules

A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions

FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit

Approvals by the China NMPA in 2023

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Recent and anticipated novel drug approvals for 2024

A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect

New drug approvals for 2021: Synthesis and clinical applications

Top companies and drugs by sales in 2023

DrugCentral 2023 extends human clinical data and integrates veterinary drugs